A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Phase 1
158
about 5.1 years
18+
3 sites in NY, TX, WA
What this study is about
Researchers are testing a treatment called AVA6000 for people with solid tumors. The trial will evaluate how safe this treatment is, how it works in the body (pharmacokinetics), and if it shows early signs of working (efficacy).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AVA6000
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Adverse events (AEs), Dose-limiting toxicities (DLTs)
Secondary: Area under the curve (AUC) of AVA6000 & Doxorubicin, Duration of Response (DoR), Elimination half-life (t1/2) of AVA6000 & Doxorubicin, Maximum drug concentration (Cmax) of AVA6000 & Doxorubicin, Objective response rate (ORR), Overall survival (OS), Progression-free-survival (PFS), Renal clearance (CLr) of AVA6000 & Doxorubicin
Oncology